Cost Curve

A Key Deadline for Companies Seeking MFN Deals Has Arrived

And Pfizer’s CEO sends a letter to Germany’s leader: ”We are ​reviewing ... certain planned investments in Germany”

Brian Reid

Politico Says the U.S. and Germany Are In ‘Secret Talks’ About MFN

And PCMA releases a document that is a master class in finger-pointing

Brian Reid

CMS Will Need to Bridge Beyond the ‘Bridge’ Demo to Preserve Long-Term Access to Obesity Meds in Medicare

And I have the numbers on TrumpRx’s web visit numbers for May

Brian Reid

It’s All Obesity Today: Drama at ADA, Pricing Implications for Pfizer’s Med, and WSJ on Shrinking Employer Coverage

Plus: ‘Why would you threaten 50% of your revenue if you think you cannot get a reasonable price in the UK or France?’

Brian Reid

Supreme Court Addresses ‘Skinny Labeling’ for Generic Drugs

And Pfizer’s Impact Report is out, detailing how the company’s portfolio-wide net price shifted in 2025

Brian Reid

An Apex Grab Bag on Value-Based Insurance, Investments in Europe, and Ongoing 340B Battles

Brian Reid

TrumpRx Traffic Numbers, Touted by Oz, Appear to Be Falling

And the top of the Fortune 500 list is a who’s-who companies profiting from 340B

Brian Reid

Lilly Says Smaller Clinics Have No Problems With 340B Transparency Acts, Even as Big, Profitmaxxing Hospitals Object

Brian Reid

The Irony of PCMA Celebrating a PBM Selection Process Won By a Big-PBM Critic

And assessing the unknowns around the plan to reimburse obesity meds in Medicare, which kicks off in a month

Brian Reid